TriSalus study shows promising results for thyroid disease treatment

WESTMINSTER, Colo. - TriSalus Life Sciences Inc. (NASDAQ:TLSI), a $149.46 million market cap medical technology company, announced clinical data showing its Pressure-Enabled Drug Delivery technology demonstrated effectiveness in treating symptomatic thyroid disease through a minimally invasive approach. According to InvestingPro data, analysts have set price targets ranging from $9 to $16, suggesting significant upside potential despite recent market challenges.

The retrospective single-center study, published in the Journal of the Endocrine Society, evaluated the use of the company’s TriNav Infusion System for thyroid artery embolization in 22 patients with benign thyroid nodules or multinodular goiters. The company maintains a strong gross profit margin of 85.6% and achieved 46.2% revenue growth in the last twelve months, supporting its continued investment in medical innovation.

According to the study results, the procedure achieved 100% technical and clinical success, with a 73% mean reduction in thyroid gland volume at six months. Additionally, 71% of patients with hyperthyroidism achieved normal thyroid function following treatment.

The procedure targeted the inferior thyroid arteries to reduce gland size and alleviate symptoms in patients who were not candidates for surgery or conventional therapies. No major complications were reported, though 81% of patients experienced mild post-procedure symptoms such as neck discomfort that resolved within two weeks.

"This study offers critical insights into how TriNav’s Pressure-Enabled Drug Delivery approach may help address therapeutic delivery challenges for patients with thyroid disease," said Richard Marshall, TriSalus Medical Director, in the press release.

The company noted that a multi-institutional registry study called PROTECT has been initiated to further validate these findings across multiple centers.

TriSalus Life Sciences develops technology that integrates with standard-of-care therapies for solid tumors. The company currently has two FDA-cleared devices using its proprietary delivery approach: the TriNav Infusion System for liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.

In other recent news, TriSalus Life Sciences Inc. has completed its exchange offer for its Preferred Stock, with an impressive 98.82% participation from shareholders. The exchange allowed preferred shareholders to swap each preferred share for 3.3 shares of common stock. This move follows TriSalus’s earlier announcement of the exchange offer aimed at simplifying its capital structure. Additionally, the company held its Annual Meeting of Shareholders, where two directors were elected for three-year terms, and the independent auditor was ratified. In other developments, Cantor Fitzgerald reiterated its Overweight rating on TriSalus, maintaining a price target of $9.00, following the launch of the TriNav FLX Infusion System. This new system is part of the company’s advancements in Pressure-Enabled Drug Delivery technology. Furthermore, TriSalus has announced a leadership change with the appointment of David B. Patience as the new Chief Financial Officer, effective July 1, 2025. Dan Giordano will serve as Acting CFO until Patience assumes his role.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.